H.C. Wainwright’s Ram Selvaraju is confident on OMER’s Phase 2 results hinting at “substantial” survival benefit for OMS721 in HSCT-TMA.
One analyst anticipates AAPL’s “Other Product” revenues are on route to doubling; another analyst believes TSLA can achieve its long-awaited Model 3 production goal.
Though SHOP delivered a strong 4Q earnings show, RBC Capital’s Ross MacMillan still spots downside, even as he boosts his price target on the stock.
H.C. Wainwright’s Ram Selvaraju now sees 4% downside for APRI stock, disappointed and surprised by the FDA’s CRL for Vitaros.
Following a second robust quarterly beat in a row for MULE, Canaccord’s Richard Davis now angles for 8% upside potential for shares.